

---

## Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

### Grant Award Details

---

Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

**Grant Type:** Clinical Trial Stage Projects

**Grant Number:** CLIN2-08334

**Project Objective:** To complete a Phase II clinical trial in Duchenne Muscular Dystrophy patients with cardiomyopathy, in which allogeneic Cardiosphere Derived Cells (CDCs) [aka CAP-1002] are infused one time via multi-vessel intracoronary delivery.

**Investigator:**

<b>Name:</b>	Linda Marban
<b>Institution:</b>	Capricor, Inc
<b>Type:</b>	PI

---

**Disease Focus:** Heart Disease, Heart disease associated with Duchenne muscular dystrophy

**Human Stem Cell Use:** Adult Stem Cell

**Award Value:** \$3,376,259

**Status:** Closed

### Progress Reports

---

**Reporting Period:** Operational Milestone #1

[View Report](#)

**Reporting Period:** Final Operational Milestone #5

[View Report](#)

---

### Grant Application Details

---

**Application Title:** Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

**Public Abstract:**            **Therapeutic Candidate or Device**

Allogeneic Cardiosphere-Derived Cells (CDCs, CAP-1002)

**Indication**

Duchenne Muscular Dystrophy Cardiomyopathy

**Therapeutic Mechanism**

Secretion of identified bioactive elements will reduce myocardial fibrosis and improve cardiac function.

**Unmet Medical Need**

Heart failure is the leading cause of death among young men with Duchenne Muscular Dystrophy. No specific therapies exist to treat this element of the disease. CAP-1002 is intended to treat the cardiomyopathy associated with DMD.

**Project Objective**

Phase 2 study completed

**Major Proposed Activities**

- manufacture CAP-1002 in quantities sufficient to treat all subjects enrolled in the trial
- enroll and treat all subjects per the clinical protocol
- enroll and treat all subjects per the clinical protocol

**Statement of Benefit to California:**    The applicant is a California-based organization. At least one clinical site within California will participate in the study.

---

**Source URL:** <https://www.cirm.ca.gov/our-progress/awards/allogeneic-cardiosphere-derived-cells-duchenne-muscular-dystrophy-cardiomyopathy>